You might be staring at one all day: a dirty computer screen, with its fine layer of dust and smudges, could be more than an eyesore or a reminder of how long you’ve been working—it can actually illustrate the science at play behind a test for examining the body’s wider immune response to the novel […]

You might be staring at one all day: a dirty computer screen, with its fine layer of dust and smudges, could be more than an eyesore or a reminder of how long you’ve been working—it can actually illustrate the science at play behind a test for examining the body’s wider immune response to the novel […]

Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of patients with higher-risk myelodysplastic syndrome (MDS) and refractory higher-risk […]